{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:47:39Z","timestamp":1768074459648,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>Arthrobacter woluwensis<\/jats:italic> (<jats:italic>A.woluwensis<\/jats:italic>) is gram-positive rod that is endemic to natural environments such as soil, but reports of infections caused by this species are limited, and effective treatment methods have not been established.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>An 89-year-old man was hospitalized for dysmobility due to anorexia and was started on peripheral intravenous nutrition. He had a fever of 39.5\u00a0\u00b0C, shivering, and hypotension. Gram-positive rods were detected in two sets of blood cultures. The treatment using vancomycin (VCM) was started due to suspicion of catheter-related bloodstream infection. The organism was identified as <jats:italic>A.woluwensis<\/jats:italic> by MALDI-TOF MS. The MIC<jats:sub>50<\/jats:sub> for VCM was 2\u00a0\u00b5g\/mL. Treatment was continued with the goal of achieving an area under the concentration-time curve (AUC) of \u2265\u2009400 \u00b5g\u00b7h\/mL, which is an indicator of the efficacy and safety of VCM in treating MRSA infection. The fever resolved after starting treatment, and the patient\u2019s condition stabilized. Further blood cultures became negative, a transthoracic echocardiogram confirmed the exclusion of infective endocarditis, and the treatment was completed after 14 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This is the first case report using VCM for the treatment and therapeutic drug monitoring (TDM) of <jats:italic>A. woluwensis<\/jats:italic> bacteremia. Our results will provide useful information for appropriate infection treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00430-9","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:38:06Z","timestamp":1742492286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antimicrobial therapy using vancomycin and therapeutic drug monitoring (TDM) in patient with bacteremia caused by Arthrobacter woluwensis:a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Junichiro","family":"Date","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"430_CR1","first-page":"510","volume-title":"Manual of clinical microbiology 12th ed","author":"CC Carroll","year":"2019","unstructured":"Carroll CC, Pfaller MA, Louise M, McAdam AJ, Patel R, Richter SS, Warnock DW. Manual of clinical microbiology 12th ed. Volume 1. Washington, D.C.: ASM; 2019. pp. 510\u20131."},{"key":"430_CR2","doi-asserted-by":"publisher","unstructured":"Funke G, Hutson RA, Bernard KA, Pfyffer GE, Wauters G, Collins MD. Isolation of Arthrobacter spp. from clinical specimens and description of Arthrobacter cumminsii sp. nov. and Arthrobacter woluwensis sp. nov. Journal of Clinical Microbiology. 1996; 34(10):2356\u20132363.Available from: https:\/\/doi.org\/10.1128\/jcm.34.10.2356-2363.1996","DOI":"10.1128\/jcm.34.10.2356-2363.1996"},{"key":"430_CR3","doi-asserted-by":"publisher","unstructured":"Bernasconi E, Valsangiacomo C, Peduzzi R, Carota A, Moccetti T, Funke G. Arthrobacter woluwensis subacute infective endocarditis: case report and review of the literature. Clinical Infectious Diseases 2004; 38(4): e27\u2013e31. Available from: https:\/\/doi.org\/10.1086\/381436","DOI":"10.1086\/381436"},{"key":"430_CR4","doi-asserted-by":"publisher","unstructured":"Shin KS, Hong SB, Son BR. A Case of Catheter-Related Bacteremia by Arthrobacter woluwensis. Annals of Laboratory Medicine. 2006; 26(2):103\u2013106. Available from: https:\/\/doi.org\/10.3343\/kjlm.2006.26.2.103","DOI":"10.3343\/kjlm.2006.26.2.103"},{"key":"430_CR5","doi-asserted-by":"publisher","unstructured":"Mages IS, Frodl R, Bernard KA, Funke G. Identities of Arthrobacter spp. and Arthrobacter-like bacteria encountered in human clinical specimens. Journal of Clinical Microbiology. 2008; 46(9):2980\u20132986. Available from: https:\/\/doi.org\/10.1128\/JCM.00658-08","DOI":"10.1128\/JCM.00658-08"},{"issue":"3","key":"430_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3947\/ic.2012.44.3.205","volume":"44","author":"CH Park","year":"2012","unstructured":"Park CH, Han MS, Kim JK, Jeong SJ, Ku NS, Kim H, et al. Development of Arthrobacter woluwensis bacteremia in a patient with multiple myeloma: A case report and comprehensive literature review. Infect Chemother. 2012;44(3):205\u20139. Available from: https:\/\/doi.org\/10.3947\/ic.2012.44.3.205.","journal-title":"Infect Chemother"},{"key":"430_CR7","doi-asserted-by":"publisher","unstructured":"Li SY, Kao CC, Hu YC, Lai CH, Jiang YP, Mao YC et al. Arthrobacter woluwensis bacteremia: A clinical and genomic report. Pathogens. 2021;10(4):443. Available from: https:\/\/doi.org\/10.3390\/pathogens10040443","DOI":"10.3390\/pathogens10040443"},{"key":"430_CR8","doi-asserted-by":"publisher","unstructured":"Durand C, Kouchit Y, Prots L, Degand N, Dellamonica P, Demonchy E et al. A case of infective endocarditis caused by Arthrobacter woluwensis. European Journal of Clinical Microbiology and Infectious Diseases. 2021 Jun; 40(6):1329\u20131331. Available from: https:\/\/doi.org\/10.1007\/s10096-021-04154-0","DOI":"10.1007\/s10096-021-04154-0"},{"key":"430_CR9","doi-asserted-by":"publisher","unstructured":"Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S et al. Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics.2022;14(3):489. Available from: https:\/\/doi.org\/10.3390\/pharmaceutics14030489","DOI":"10.3390\/pharmaceutics14030489"},{"key":"430_CR10","doi-asserted-by":"publisher","unstructured":"Oda K, Hashiguchi Y, Kimura T, Tsuji Y, Shoji K, Takahashi Y et al. Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application. Pharmaceutical research. 2021;38(4):637\u2013646. Available from: https:\/\/doi.org\/10.1007\/s11095-021-03030-y","DOI":"10.1007\/s11095-021-03030-y"},{"key":"430_CR11","doi-asserted-by":"publisher","unstructured":"Ishaq H, Tariq W, Talha KM, Palraj BRV, Sohail MR, Baddour LM, Mahmood M. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis. Infection. 2021;49(5):803\u201311. Available from: https:\/\/doi.org\/10.1007\/s15010-020-01568-4","DOI":"10.1007\/s15010-020-01568-4"},{"key":"430_CR12","doi-asserted-by":"publisher","unstructured":"Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 \u00b5g\/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. Journal of Infection and Chemotherapy. 2011;17(1):52\u201357.Available from: https:\/\/doi.org\/10.1007\/s10156-010-0086-0","DOI":"10.1007\/s10156-010-0086-0"},{"key":"430_CR13","doi-asserted-by":"publisher","unstructured":"Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Ortega M, L\u00f3pez J, Pitart C, Navas E, Mensa J. Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases. 2008;46(2):193\u2013200. Available from: https:\/\/doi.org\/10.1086\/524667","DOI":"10.1086\/524667"},{"key":"430_CR14","doi-asserted-by":"publisher","unstructured":"Hoshi T, Watanabe K, Fukumura Y, Miyazaki K, Takahashi M, Taniguchi S et al. Effect of the Minimum Inhibitory Concentration of Vancomycin on the Clinical Outcome of Enterococcus faecium Bacteremia. In Vivo. 2023;37(5):2197\u20132202. Available from: https:\/\/doi.org\/10.21873\/invivo.13319","DOI":"10.21873\/invivo.13319"},{"issue":"5","key":"430_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ejhpharm-2022-003672","volume":"31","author":"N Tochikura","year":"2024","unstructured":"Tochikura N, Matsumoto C, Iwabuchi S, Aso H, Fukushima S, Ootsuka S, et al. Pharmacokinetic\/pharmacodynamic analysis of Vancomycin in patients with Enterococcus faecium bacteraemia: a retrospective cohort study. Eur J Hosp Pharm. 2024;31(5):440\u20136. https:\/\/doi.org\/10.1136\/ejhpharm-2022-003672. Available from:.","journal-title":"Eur J Hosp Pharm"},{"key":"430_CR16","doi-asserted-by":"publisher","unstructured":"Komatsu T, Naito A, Akamada Y, Nihonyanagi S, Otori K. Association between ratio of area under the concentration\u2013time curve to minimum inhibitory concentration of vancomycin and clinical outcomes in Enterococcus faecium bacteremia. Journal of Infection and Chemotherapy. 2023;29(12):1181\u20131184. Available from:https:\/\/doi.org\/10.1016\/j.jiac.2023.07.010","DOI":"10.1016\/j.jiac.2023.07.010"},{"key":"430_CR17","doi-asserted-by":"publisher","unstructured":"Milosavljevic MN, Milosavljevic JZ, Kocovic AG, Stefanovic SM, Jankovic SM, Djesevic M et al. Antimicrobial treatment of corynebacterium striatum invasive infections: A systematic review. Revista do Instituto de Medicina Tropical de Sao Paulo. 2021;18(63): e49. Available from: https:\/\/doi.org\/10.1590\/S1678-9946202163049","DOI":"10.1590\/S1678-9946202163049"},{"key":"430_CR18","doi-asserted-by":"publisher","unstructured":"Salem N, Salem L, Saber S, Ismail G, Bluth H. M. Corynebacterium urealyticum: A comprehensive review of an understated organism. Infection and Drug Resistance. 2015; 8:129\u2013145. Available from: https:\/\/doi.org\/10.2147\/IDR.S74795","DOI":"10.2147\/IDR.S74795"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00430-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:38:08Z","timestamp":1742492288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00430-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00430-9","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the patient\u2019s medical condition and level of consciousness, it was not possible to obtain direct informed consent. Instead, proxy consent was obtained from the patient\u2019s legal representative (family member) in accordance with Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Written informed consent was obtained from the family.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient\u2019s family.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}